Our thoracic pathology team is one of the best in the world, with expertise not only in thoracic pathology but also in thoracic cytology. We work closely with our clinical colleagues to provide multidisciplinary diagnostic expertise to MSK patients and with the Molecular Diagnostics Laboratory to assure optimal molecular diagnostic testing using the latest techniques such as next-generation sequencing.
My research in thoracic neoplasms has focused on lung cancer, malignant mesothelioma, and mediastinal thymic tumors. I have worked on classification of thoracic disorders and served as Lead Editor of the 1999 WHO Classification of Lung and Pleural Tumors as well as the 2004 and 2015 WHO Classification: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. I also led the 2011 IASLC/ATS/ERS lung adenocarcinoma classification.
My interest in non-neoplastic lung disease has focused on interstitial lung disease. This resulted in my leading the 2002 American Thoracic Society and European Respiratory Society International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonias; the 2008 ATS Project on Nonspecific Interstitial Pneumonia; and the 2012 ATS/ERS: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias.
I have devoted my career to training the next generation of thoracic pathologists and helped develop the first ACGME-accredited Pulmonary Pathology Fellowship program in 2000 while at the Armed Forces Institute of Pathology. When I moved to MSK in 2005, my colleagues and I established an ACGME-accredited Thoracic Pathology Fellowship program.
- Clinical Expertise: Anatomic Pathology; Thoracic Pathology
- Languages Spoken: English
- Education: MD, University of Florida College of Medicine (Gainesville)
- Residencies: New England Deaconess Hospital/Harvard Medical School; Mayo Clinic
- Fellowships: Mayo Clinic
- Board Certifications: Anatomic and Clinical Pathology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more